0026-895X/03/6402-407-414$20.00
Mol Pharmacol 64:407-414, 2003
Aspirin Protects Caco-2 Cells from Apoptosis after Serum Deprivation through the Activation of a Phosphatidylinositol 3-Kinase/AKT/p21Cip/WAF1Pathway
Paolo Ricchi,
Antonella Di Palma,
Tiziana Di Matola,
Anna Apicella,
Rosaria Fortunato,
Raffaele Zarrilli, and
Angela Maria Acquaviva
Dipartimento di Biologia e Patologia Cellulare e Molecolare "L.
Califano", Istituto di Endocrinologia ed Oncologia Sperimentale
"G. Salvatore" del Consiglio Nazionale delle Ricerche,
Università "Federico II", Napoli, Italy
Our previous studies indicated that millimolar doses of aspirin induced
growth arrest and resistance to anticancer drug treatment in Caco-2 cells. The
present study was designed to better elucidate at the molecular level the
effect of aspirin treatment on pathways that regulate cell death during serum
withdrawal. Caco-2 cells were cultured under serum deprivation in the presence
or absence of aspirin. Effects on cell cycle, phosphatidylinositol 3-kinase
(PI3-kinase) and mitogen-activated protein (MAP) kinase pathways were
investigated. We found that aspirin, but not the selective cyclooxygenase-2
inhibitor N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methane sulfonamide
(NS-398); prevented apoptosis and G2/M transition after prolonged
Caco-2 cells serum deprivation. Aspirin-dependent inhibition of apoptosis and
G2/M transition was prevented by treatment with the PI3-kinase
inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
(LY294002), but not with the MAP kinase kinase inhibitor
2'-amino-3'-methoxyflavone (PD98059). The effects of aspirin were
mediated at molecular levels, through activation of PI3-kinase/AKT pathway and
increase in the p21Cip/WAF1 level. The ability of
aspirin to activate AKT protein was observed also in presence of etoposide
cotreatment. Our data indicate a new intracellular target of aspirin with
potential clinical impact for treatment schedules involving both anticancer
agents and aspirin in malignancies.
Received March 3, 2003;
accepted April 30, 2003
Address correspondence to: Prof. Angela M. Acquaviva, Dipartimento di
Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e
Chirurgia, Università "Federico II", via S. Pansini 5,
80131 Napoli, Italy. E-mail:
angacqua{at}unina.it
This article has been cited by other articles:

|
 |

|
 |
 
V. Leone, A. di Palma, P. Ricchi, F. Acquaviva, M. Giannouli, A. M. Di Prisco, F. Iuliano, and A. M. Acquaviva
PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation
Am J Physiol Gastrointest Liver Physiol,
October 1, 2007;
293(4):
G673 - G681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. di Palma, G. Matarese, V. Leone, T. Di Matola, F. Acquaviva, A. M. Acquaviva, and P. Ricchi
Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling
Mol. Cancer Ther.,
May 1, 2006;
5(5):
1318 - 1324.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics